迈威生物股价跌5%，东方基金旗下1只基金重仓，持有1.71万股浮亏损失3.59万元

Group 1 - The core point of the news is that Maiwei Biotech's stock has experienced a decline of 5%, with the current share price at 39.88 yuan, a trading volume of 272 million yuan, a turnover rate of 3.28%, and a total market capitalization of 15.936 billion yuan [1] - Maiwei Biotech, established on May 12, 2017, and listed on January 18, 2022, is primarily engaged in the research, production, and sales of therapeutic biological products, with 99.91% of its revenue coming from product sales and 0.09% from services [1] Group 2 - From the perspective of major fund holdings, one fund under Dongfang Fund has a significant position in Maiwei Biotech. The Dongfang Innovation Medical Stock A (018045) reduced its holdings by 33,100 shares in the third quarter, now holding 17,100 shares, which represents 3.08% of the fund's net value, ranking as the eighth largest holding [2] - The Dongfang Innovation Medical Stock A (018045) was established on May 8, 2023, with a latest scale of 10.702 million. Year-to-date returns are at 8.85%, ranking 1479 out of 5542 in its category, while the one-year return is 34.05%, ranking 2266 out of 4235 [2]